• Baseline A1C ∼9.1%
  • Insulin doses (basal and premeal) did not change significantly in either group during the trial
  • Reference [1]
Pramlintide added to insulin and oral meds
Pramlintide 120 mcg before meals
(N=166)
Placebo
(N=161)
HgA1C
(average change at 6 months)
-0.66% -0.32%

  • Baseline A1C ∼9.0%
  • Insulin doses (basal and premeal) did not change significantly in either group during the trial
  • Reference [1]
Pramlintide added to insulin
Pramlintide 60 mcg three times a day
(N=164)
Placebo
(N=154)
HgA1C
(average change at 6 months)
-0.44%
-0.19%





  • Trials lasting 26 - 52 weeks
  • Reference [1]
Trials in type one diabetics
Side effect Pramlintide 30 - 60 mcg 3 times a day
(N=716)
Placebo
(N=538)
Nausea 48% 17%
Decreased appetite 17% 2%
Vomiting 11% 7%

  • Trials lasting 26 - 52 weeks
  • Reference [1]
Trials in type two diabetics
Side effect Pramlintide 120 mcg 2 times a day
(N=292)
Placebo
(N=284)
Nausea 28% 12%
Decreased appetite 9% 2%
Vomiting 8% 4%